Payment overview · 2025
General Payments
$45.23
2 reported records · 2 companies
Healthcare provider profile · identity verified
Talal Alsbiei, MD
Allopathic & Osteopathic Physicians|Internal Medicine · TUCSON, AZ · NPI 1740367549
Verified facts
What the public records show
CMS Open Payments records show Talal Alsbiei, MD received $45.23 in general payments during 2025 across 2 reported records.
GlaxoSmithKline, LLC. accounted for 59.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $26.98 | 59.6% | 1 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $18.25 | 40.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $45.23 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JEMPERLI Normalized: jemperli |
Biological | GlaxoSmithKline, LLC. | $26.98 | 1 | 2025 |
Source payment records
|
|||||
| DAYBUE Normalized: daybue |
Drug | ACADIA Pharmaceuticals Inc | $18.25 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 689 | 101 |
| Atorvastatin Calcium | Atorvastatin Calcium | 633 | 159 |
| Gabapentin | Gabapentin | 487 | 94 |
| Amlodipine Besylate | Amlodipine Besylate | 354 | 99 |
| Eliquis | Apixaban | 323 | 57 |
| Enoxaparin Sodium | Enoxaparin Sodium | 312 | 24 |
| Furosemide | Furosemide | 271 | 47 |
| Metoprolol Tartrate | Metoprolol Tartrate | 255 | 57 |
| Lisinopril | Lisinopril | 247 | 70 |
| Trazodone Hcl | Trazodone Hcl | 220 | 47 |
| Losartan Potassium | Losartan Potassium | 215 | 61 |
| Metformin Hcl | Metformin Hcl | 207 | 48 |
| Pantoprazole Sodium | Pantoprazole Sodium | 176 | 54 |
| Sertraline Hcl | Sertraline Hcl | 169 | 44 |
| Tamsulosin Hcl | Tamsulosin Hcl | 156 | 38 |
| Carvedilol | Carvedilol | 149 | 37 |
| Levetiracetam | Levetiracetam | 134 | 27 |
| Oxycodone Hcl | Oxycodone Hcl | 134 | 27 |
| Potassium Chloride | Potassium Chloride | 121 | 38 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 115 | 48 |
| Baclofen | Baclofen | 115 | 22 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 111 | 23 |
| Divalproex Sodium | Divalproex Sodium | 107 | 27 |
| Quetiapine Fumarate | Quetiapine Fumarate | 107 | 36 |
| Montelukast Sodium | Montelukast Sodium | 106 | 32 |
| Duloxetine Hcl | Duloxetine Hcl | 104 | 32 |
| Mirtazapine | Mirtazapine | 102 | 27 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 97 | 36 |
| Midodrine Hcl | Midodrine Hcl | 91 | 24 |
| Escitalopram Oxalate | Escitalopram Oxalate | 90 | 25 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 88 | 18 |
| Metoprolol Succinate | Metoprolol Succinate | 86 | 33 |
| Hydrochlorothiazide | Hydrochlorothiazide | 85 | 29 |
| Ondansetron Hcl | Ondansetron Hcl | 82 | 47 |
| Xarelto | Rivaroxaban | 81 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 76 | 29 |
| Pravastatin Sodium | Pravastatin Sodium | 75 | 15 |
| Tramadol Hcl | Tramadol Hcl | 74 | 24 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 71 | 23 |
| Glipizide | Glipizide | 68 | 12 |
| Alprazolam | Alprazolam | 67 | 13 |
| Clonidine Hcl | Clonidine Hcl | 67 | 31 |
| Spironolactone | Spironolactone | 66 | 15 |
| Omeprazole | Omeprazole | 64 | 35 |
| Simvastatin | Simvastatin | 64 | 24 |
| Buspirone Hcl | Buspirone Hcl | 63 | 14 |
| Memantine Hcl | Memantine Hcl | 61 | 15 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 61 | 20 |
| Warfarin Sodium | Warfarin Sodium | 59 | suppressed |
| Prednisone | Prednisone | 58 | 34 |
| Cephalexin | Cephalexin | 55 | 40 |
| Lactulose | Lactulose | 55 | 18 |
| Famotidine | Famotidine | 53 | 25 |
| Risperidone | Risperidone | 53 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 52 | 16 |
| Bupropion Xl | Bupropion Hcl | 51 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 49 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 48 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 48 | 17 |
| Finasteride | Finasteride | 47 | 15 |
| Methadone Hcl | Methadone Hcl | 47 | suppressed |
| Insulin Lispro | Insulin Lispro | 42 | 20 |
| Lorazepam | Lorazepam | 42 | 19 |
| Metformin Hcl Er | Metformin Hcl | 42 | 13 |
| Brilinta | Ticagrelor | 41 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 41 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 41 | suppressed |
| Allopurinol | Allopurinol | 40 | 12 |
| Donepezil Hcl | Donepezil Hcl | 40 | 14 |
| Doxycycline Hyclate | Doxycycline Hyclate | 40 | 35 |
| Pregabalin | Pregabalin | 40 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 38 | suppressed |
| Lacosamide | Lacosamide | 37 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 37 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 34 | 11 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 34 | 13 |
| Lamotrigine | Lamotrigine | 34 | suppressed |
| Methocarbamol | Methocarbamol | 34 | 18 |
| Olanzapine | Olanzapine | 34 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 34 | suppressed |
| Aripiprazole | Aripiprazole | 32 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 32 | 22 |
| Fluoxetine Hcl | Fluoxetine Hcl | 32 | suppressed |
| Latanoprost | Latanoprost | 31 | suppressed |
| Admelog | Insulin Lispro | 30 | suppressed |
| Enulose | Lactulose | 30 | suppressed |
| Januvia | Sitagliptin Phosphate | 30 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 30 | 11 |
| Myrbetriq | Mirabegron | 30 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 30 | suppressed |
| Entresto | Sacubitril/Valsartan | 29 | suppressed |
| Lubiprostone | Lubiprostone | 29 | suppressed |
| Nifedipine Er | Nifedipine | 29 | suppressed |
| Primidone | Primidone | 29 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 29 | suppressed |
| Budesonide | Budesonide | 28 | suppressed |
| Ondansetron Odt | Ondansetron | 28 | 16 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 28 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 27 | suppressed |
| Rexulti | Brexpiprazole | 27 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 26 | 26 |
| Breyna | Budesonide/Formoterol Fumarate | 26 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 26 | suppressed |
| Clonazepam | Clonazepam | 26 | suppressed |
| Jardiance | Empagliflozin | 26 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 25 | 22 |
| Ketoconazole | Ketoconazole | 25 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 25 | suppressed |
| Humalog | Insulin Lispro | 24 | 15 |
| Albuterol Sulfate | Albuterol Sulfate | 23 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 23 | suppressed |
| Lovastatin | Lovastatin | 23 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 23 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 23 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 23 | 16 |
| Sumatriptan Succinate | Sumatriptan Succinate | 23 | suppressed |
| Acarbose | Acarbose | 22 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 22 | suppressed |
| Hydrocortisone | Hydrocortisone | 22 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 22 | suppressed |
| Ozempic | Semaglutide | 22 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 22 | suppressed |
| Clonidine | Clonidine | 21 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 21 | suppressed |
| Tiotropium Bromide | Tiotropium Bromide | 21 | suppressed |
| Topiramate | Topiramate | 21 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 20 | suppressed |
| Atenolol | Atenolol | 19 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 19 | suppressed |
| Heparin Sodium | Heparin Sodium,porcine | 19 | suppressed |
| Meloxicam | Meloxicam | 19 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 19 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 19 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 19 | suppressed |
| Levofloxacin | Levofloxacin | 18 | 14 |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Azithromycin | Azithromycin | 17 | 12 |
| Fluconazole | Fluconazole | 17 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 17 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 17 | suppressed |
| Acetylcysteine | Acetylcysteine | 16 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 16 | suppressed |
| Glimepiride | Glimepiride | 16 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 16 | suppressed |
| Irbesartan | Irbesartan | 16 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 16 | 12 |
| Arformoterol Tartrate | Arformoterol Tartrate | 15 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 15 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 15 | suppressed |
| Trulicity | Dulaglutide | 15 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 14 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 14 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 14 | suppressed |
| Amantadine | Amantadine Hcl | 13 | suppressed |
| Diazepam | Diazepam | 13 | suppressed |
| Digoxin | Digoxin | 13 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 13 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Methotrexate | Methotrexate Sodium | 13 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 13 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Simbrinza | Brinzolamide/Brimonidine Tart | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 12 | 12 |
| Ertapenem | Ertapenem Sodium | 12 | suppressed |
| Fentanyl | Fentanyl | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 12 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 12 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Testosterone | Testosterone | 12 | suppressed |
| Timolol Maleate | Timolol Maleate | 12 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 12 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 11 | suppressed |
| Celecoxib | Celecoxib | 11 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Ezetimibe | Ezetimibe | 11 | suppressed |
| Haloperidol Lactate | Haloperidol Lactate | 11 | suppressed |
| Klayesta | Nystatin | 11 | suppressed |
| Leflunomide | Leflunomide | 11 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 11 | suppressed |
| Rivastigmine | Rivastigmine | 11 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 11 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $45.23 · 2 records | GlaxoSmithKline, LLC. | DAYBUE, JEMPERLI | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error